Repetitive brief ischemia: intermittent reperfusion during ischemia ameliorates the extent of injury in the perfused kidney.
Acute renal failure commonly follows reduced renal perfusion or ischemia. Reperfusion is essential for recovery but can itself cause functional and structural injury to the kidney. The separate contributions of ischemia and of reperfusion were examined in the isolated perfused rat kidney. Three groups were studied: brief (5 min) ischemia, 20 min ischemia, and repetitive brief ischemia (4 periods of 5 min) with repetitive intervening reperfusion of 5 min. A control group had no intervention, the three ischemia groups were given a baseline perfusion of 30 min before intervention and all groups were perfused for a total of 80 min. In addition, the effects of exogenous *NO from sodium nitroprusside and xanthine oxidase inhibition by allopurinol were assessed in the repetitive brief ischemia-reperfusion model. Brief ischemia produced minimal morphological injury with near normal functional recovery. Repetitive brief ischemia-reperfusion caused less functional and morphological injury than an equivalent single period of ischemia (20 min) suggesting that intermittent reperfusion is less injurious than ischemia alone over the time course of study. Pretreatment with allopurinol improved renal function after repetitive brief ischemia-reperfusion compared with the allopurinol-untreated repetitive brief ischemia-reperfusion group. Similarly, sodium nitroprusside reduced renal vascular resistance but did not improve the glomerular filtration rate or sodium reabsorption in the repetitive brief ischemia-reperfusion model. Thus, these studies show that the duration of uninterrupted ischemia is more critical than reperfusion in determining the extent of renal ischemia-reperfusion injury and that allopurinol, in particular, counteracts the oxidative stress of reperfusion.
Willgoss
Desley A
DA
Department of Medicine, School of Medicine, University of Queensland, Royal Brisbane Hospital, Brisbane, Australia.
Zhang
Bing
B
Gobé
Glenda C
GC
Kadkhodaee
Mehri
M
Endre
Zoltan H
ZH
D000493:Allopurinol / Q000494:pharmacology; D000818:Animals; D004195:Disease Models, Animal; D016166:Free Radical Scavengers / Q000494:pharmacology; D005919:Glomerular Filtration Rate / Q000187:drug effects / Q000502:physiology; D007674:Kidney Diseases / Q000209:etiology / Q000503:physiopathology; D007679:Kidney Medulla / Q000293:injuries / Q000503:physiopathology; D007687:Kidney Tubules, Proximal / Q000293:injuries / Q000473:pathology; D008297:Male; D009318:Natriuresis / Q000187:drug effects / Q000502:physiology; D009336:Necrosis; D009599:Nitroprusside / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D015424:Reperfusion / Q000009:adverse effects; D015427:Reperfusion Injury / Q000209:etiology* / Q000503:physiopathology; D012720:Severity of Illness Index; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology; D014665:Vasodilator Agents / Q000494:pharmacology
D016166:Free Radical Scavengers; D014665:Vasodilator Agents; D009599:Nitroprusside; D000493:Allopurinol